Drug: Isentress (raltegravir potassium)
Indication: HIV
Company: Merck
Approval Date: October 12, 2007
Scoop: Isentress is the first agent in the class of antiretroviral agents known as integrase inhibitors. The drug is designed to slow the advancement of HIV-1 infection by blocking the HIV integrase enzyme that the virus needs in order to multiply. The drug is forecasted to reach $900 million in sales by 2012.
More news:
FDA approves Isentress. Report [1]
FDA panel endorses Merck's new AIDS drug. Report [2]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-fda-approves-isentress
[2] http://www.fiercebiotech.com/story/fda-panel-endorses-mercks-new-aids-drug/2007-09-06
[3] http://www.fiercebiotech.com/special-reports/doribax-2007-fda-approvals
[4] http://www.fiercebiotech.com/special-reports/2007-fda-approvals
[5] http://www.fiercebiotech.com/special-reports/ixempra-2007-fda-approvals